Do you want to read an article? Please log in or register.
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
Genitourinary Cancer
Related content
Genitourinary Cancer
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy
BJU Int
Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R
doi: 10.1111/bju.16895
COMMENTED
Genitourinary Cancer
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Clin Oncol
Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group
doi: 10.1200/JCO-25-01324
Genitourinary Cancer
The impact of treatment for muscle-invasive bladder cancer on health-related quality of life
BJU Int
Nuijens ST, van Hoogstraten LMC, Terpstra NB, Beeren I, Vrieling A, Wijnen EM, Meijer RP, Kiemeney LA, Witjes JA, Aben KKH
doi: 10.1111/bju.16736
Genitourinary Cancer
Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
J Urol
Khene ZE, Bhanvadia R, Attia S, Ito W, Trevino I, Woldu SL, Margulis V, Lotan Y
doi: 10.1097/JU.0000000000004472
Genitourinary Cancer
A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer
Eur Urol
Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, Psutka SP, Sundi D, Tyson MD, Inman BA
doi: 10.1016/j.eururo.2025.02.010
Genitourinary Cancer
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
N Engl J Med
Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Ürün Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE, IMvigor011 Investigators
doi: 10.1056/NEJMoa2511885
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
Gynecologic Cancer
Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study
Eur J Cancer
Hardie AN, Wenzel HHB, Schnack TH, Van der Aa MA, Jensen PT, Bekkers RLM, Falconer H, Dutch, dANish and sweDish gynaEcoLogIcal ONcology (DANDELION) research group
doi: 10.1016/j.ejca.2025.115664
Genitourinary Cancer
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer
BJU Int
McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA
doi: 10.1111/bju.70044